Company news
Abionyx Pharma Sa (EURONEXT:ABNX) news
Abionyx Pharma Sa news releases on 6ix. Latest, Oct 2, 2026: ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share…
Press releases & updates
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
October 2, 2026
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
October 1, 2026
ABIONYX Pharma : Information relative au nombre total de droits de vote et d’actions composant le capital social
October 1, 2026
ABIONYX Pharma Announces the Settlement of an Anticipated Amortization Payment in Accordance With the Terms of Its Bonds Financing Agreement
October 1, 2026
ABIONYX Pharma annonce le règlement d’un amortissement anticipé conformément aux termes de son contrat de Financement Obligataire
October 1, 2026
ABIONYX Pharma Announces the Settlement of an Anticipated Amortization Payment in Accordance With the Terms of Its Bonds Financing Agreement
October 2, 2026
ABIONYX Pharma: Half Year Results 2026
September 23, 2026
ABIONYX Pharma Reaches Another Key Milestone in the Industrialization of CER-001 by Entering into a Strategic Partnership with TEXCELL (ABL Diagnostics) for the Viral Safety and Clearance of Biologics
September 10, 2026
ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the First Half of 2026
August 27, 2026
Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
August 4, 2026
ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA
July 6, 2026
ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsis
June 30, 2026
ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M
June 18, 2026
ABIONYX Pharma : Combined Annual Shareholders’ Meeting on June 30, 2026: Availability of preparatory documents and procedures for participation and voting
June 9, 2026
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
June 2, 2026
ABIONYX Pharma Provides an Update on Its Operations and Cash Position for the First Quarter of 2026
May 28, 2026
ABIONYX Pharma Launches Fully Secured Capital Increase with Preferential Subscription Rights and Structured Debt Financing for an Aggregate Amount of up to c. EUR 33 M
May 27, 2026
ABIONYX Pharma Achieves Major Milestone in apoA-I Biomanufacturing with Breakthrough in Synthetic Sphingomyelin Production
March 27, 2026
ABIONYX Pharma: Availability of the Universal Registration Document for the year 2025
March 17, 2026
ABIONYX Pharma Announces Its 2025 Annual Results
March 12, 2026
ABIONYX Pharma Provides an Update on Its Business and Cash Position for the 4th Quarter of 2025
February 26, 2026
ABIONYX Pharma Announces Its Financial Calendar for the Year 2026
January 23, 2026
ABIONYX Pharma: Half-Yearly Report on the Liquidity Contract with TP ICAP (Europe) SA
January 7, 2026
ABIONYX Pharma Carries Out a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m
December 17, 2025
ABIONYX Pharma Is Launching a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m
December 16, 2025
ABIONYX Pharma Reports on Its Business and Cash Position for the Third Quarter of 2025
November 25, 2025
ABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis Diagnosis
November 20, 2025
ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS, the World’s First Center Dedicated to Sepsis
November 12, 2025
ABIONYX Pharma Announces Advanced Strategic Discussions with IHU SEPSIS, the World's Leading Center Dedicated to Sepsis
November 12, 2025
ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis
October 21, 2025
ABIONYX Pharma: 2025 Half-Year Financial Results
September 25, 2025
ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 2nd Quarter 2025
August 28, 2025
ABIONYX Pharma Announces the Start of Discussions With a Major Player in the Field of Sepsis for a Strategic Partnership
August 27, 2025
ABIONYX Pharma Announces Approval of All Resolutions Put to the Vote at Its Combined General Meeting
June 27, 2025
ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2025
May 28, 2025